Rep. Michael A. Rulli Sells Shares of Eli Lilly and Company (NYSE:LLY)

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on August 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on July 1st. The trade occurred in the Representative’s “MERRILL LYNCH MANAGED ACCOUNT” account.

Representative Michael A. Rulli also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 8/6/2026.
• Purchased $1,001 – $15,000 in shares of KLA (NASDAQ:KLAC) on 7/1/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/29/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 6/25/2026.

Eli Lilly and Company Stock Up 3.7%

NYSE:LLY opened at $1,230.00 on Tuesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $625.90 and a 1-year high of $1,249.45. The company has a 50-day moving average of $1,162.38 and a 200 day moving average of $1,048.95. The firm has a market cap of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. grew its holdings in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $749,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Morgan Stanley reissued an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a report on Thursday. Royal Bank Of Canada upped their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday. Bank of America boosted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Rothschild & Co Redburn upped their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio’s 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027.

Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio’s 6th Congressional District. He declared candidacy for the 2026 election.

Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli’s career experience includes working as the director of operations with Rulli Bros. Markets.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.